WallStreetZenWallStreetZen

NASDAQ: ELVN
Enliven Therapeutics Inc Stock Ownership - Who owns Enliven Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Enliven Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Lori Anne KunkelDirector2026-06-057,779$34.28
$266.66kSell
Lori Anne KunkelDirector2026-06-05354$35.82
$12.68kSell
Lori Anne KunkelDirector2026-06-051,867$35.36
$66.01kSell
Helen Louise CollinsCHIEF MEDICAL OFFICER2026-05-185,000$2.48
$12.40kBuy
Helen Louise CollinsCHIEF MEDICAL OFFICER2026-05-18223$41.21
$9.19kSell
Helen Louise CollinsCHIEF MEDICAL OFFICER2026-05-181,302$40.25
$52.40kSell
Helen Louise CollinsCHIEF MEDICAL OFFICER2026-05-183,475$39.53
$137.38kSell
Helen Louise CollinsCHIEF MEDICAL OFFICER2026-04-175,000$2.48
$12.40kBuy
Helen Louise CollinsCHIEF MEDICAL OFFICER2026-04-17140$45.81
$6.41kSell
Helen Louise CollinsCHIEF MEDICAL OFFICER2026-04-172,419$47.39
$114.64kSell

1 of 9

ELVN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ELVN insiders and whales buy or sell their stock.

ELVN Shareholders

What type of owners hold Enliven Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC16.74%10,195,751$470.33MInsider
David P. Bonita13.79%8,398,136$387.41MInsider
5am Partners VI LLC13.37%8,142,154$375.60MInsider
Orbimed Advisors LLC13.07%7,959,538$367.17MInstitution
Rishi Gupta13.06%7,951,463$366.80MInsider
Fmr LLC11.21%6,829,246$315.03MInstitution
Polar Capital Holdings PLC8.32%5,065,933$233.69MInstitution
Blackrock Inc6.05%3,684,707$169.98MInstitution
Ra Capital Management LP5.87%3,576,813$165.00MInsider
Commodore Capital LP5.38%3,275,000$151.08MInstitution

1 of 3

ELVN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ELVN50.94%49.06%Net SellingNet Selling
DFTX63.44%36.56%Net SellingNet Selling
KLRA0.00%85.31%Net BuyingNet Buying
CLDX85.13%14.87%Net Buying
IDYA92.57%7.43%Net Buying
View Top Biotech Stocks

Enliven Therapeutics Stock Ownership FAQ

Who owns Enliven Therapeutics?

Enliven Therapeutics (NASDAQ: ELVN) is owned by 103.09% institutional shareholders, 99.28% Enliven Therapeutics insiders, and 0.00% retail investors. Orbimed Advisors LLC is the largest individual Enliven Therapeutics shareholder, owning 10.20M shares representing 16.74% of the company. Orbimed Advisors LLC's Enliven Therapeutics shares are currently valued at $431.89M.

If you're new to stock investing, here's how to buy Enliven Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.